M-7 [Mutatect]細胞
生長狀態： 貼壁生長
數量： 大量
ATCC Number： CRL-2804?
相關**： 纖維肉瘤
細胞形態： 成纖維樣
是否是腫瘤細胞： 0
物種來源： 小鼠
運輸方式： 凍存運輸
品系： C57BL/10
Designations: M-7 [Mutatect]
Depositors: HC Birnboim
M-7 [Mutatect]細胞Biosafety Level: 2 [Cells contain SV-40 and CMV viral DNA sequences ]
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Mus musculus
Morphology: fibroblast
Source: Disease: fibrosarcoma
Strain: C57BL/10
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Isolation: Isolation date: 2003
Applications: tumor model
Tumorigenic: Yes
Gender: male
Comments: M-7 [Mutatect]細胞The Mutatect mouse tumor model is a series of cell lines (eight are available from ATCC ) derived from a murine fibrosarcoma that can grow in culture as well as form subcutaneous tumors in syngeneic C57BL/6 mice. MiF-6 (ATCC CRL-2802) and M-7 (ATCC CRL-2804) are derivatives of MC-TGS17-51 (ATCC CRL-2799). M7 cells were constructed by transfection of MC-TGS17-51 cells with the pCR3.1 vector alone. The vector contains cytomegalovirus (CMV) and SV40 viral sequences and the neomycin resistance gene. M7 cells are used as a control for MiF-6. MiF-6 cells were constructed by transfection of MC-TGS17-51 cells with pRNAi-5 ligated to pCR3.1 to produce a construct expressing mouse double stranded short-interfering ribonucleic acid (siRNA) formaldehyde dehydrogenase (FDH) mRNA. The pRNAi-5 construct targeted the sequence from -18 to +4 of the mRNA, including the start codon [PubMed: 14732341]. M7 and MiF-6 cells are 6-thioguanine sensitive, neomycin (G418) resistant, hypoxanthine phosphoribosyl transferase positive (HPRT+) and will grow in HAT selection medium. The Mutatect cell lines can be used in vitro/in vivo for the detection of deletion mutations of the hypoxanthine phosphoribosyl transferase (HPRT) gene. They are also useful for the study of inflammatory infiltration of solid tumors.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
Remove and discard culture medium.
Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: M-7 [Mutatect]細胞To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
Add appropriate aliquots of the cell suspension to new culture vessels.
An inoculum of 2 X 10(3) to 3 X 10(3) viable cells/cm2 is recommended.
Incubate cultures at 37?C.
Interval: Maintain cultures at a cell concentration between 1 X 10(4) and 5 X 10(5) cells/cm2
Subcultivation Ratio: A subcultivation of 1:5 to 1:8 is recommended
Medium Renewal: Two to three times weekly
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: M-7 [Mutatect]細胞liquid nitrogen vapor phase
Doubling Time: 19 hours
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
parental cell line:ATCC CRL-2799
References: 89373: Haqqani AS, et al. The role of a formaldehyde dehydrogenase-glutathione pathway in protein S-nitrosation in mammalian cells. Nitric Oxide 9: 172-181, 2003. PubMed: 14732341
